The dilemma of vasopressors and vasodilators in the therapy of shock.
D001794:Blood Pressure; D002302:Cardiac Output; D002496:Central Venous Pressure; D002746:Chlorpromazine / Q000627:therapeutic use; D006339:Heart Rate; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D007545:Isoproterenol / Q000627:therapeutic use; D008680:Metaraminol / Q000627:therapeutic use; D008729:Methoxamine / Q000627:therapeutic use; D009638:Norepinephrine / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D012769:Shock / Q000188:drug therapy* / Q000503:physiopathology; D012771:Shock, Hemorrhagic / Q000188:drug therapy; D012772:Shock, Septic / Q000188:drug therapy; D013566:Sympathomimetics / Q000627:therapeutic use; D014655:Vascular Resistance; D014662:Vasoconstrictor Agents / Q000494:pharmacology / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*
D013566:Sympathomimetics; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D010643:Phenoxybenzamine; D008680:Metaraminol; D008729:Methoxamine; D007545:Isoproterenol; D002746:Chlorpromazine; D006854:Hydrocortisone; D009638:Norepinephrine; D010646:Phentolamine